Use of Real-World Evidence to Support FDA Approval of Oncology Drugs
| Autor: | Todd D. Phillips, Eli G. Phillips, Marjorie E Zettler, Jonathan Kish, Bruce A. Feinberg, Ajeet Gajra |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
United States Food and Drug Administration business.industry Health Policy Medical record Fda approval Public Health Environmental and Occupational Health Antineoplastic Agents Real world evidence United States Clinical trial Food and drug administration Evidence-Based Practice Neoplasms Expanded access Family medicine Data quality Pragmatic Clinical Trials as Topic Humans Medicine business Oncology drugs Drug Approval |
| Zdroj: | Value in Health. 23:1358-1365 |
| ISSN: | 1098-3015 |
| DOI: | 10.1016/j.jval.2020.06.006 |
| Popis: | Objectives Real-world evidence (RWE) has gained increased attention in recent years as a complement to traditional clinical trials. The use of RWE to establish the efficacy of oncology drugs for Food and Drug Administration (FDA) approval has not been described. In this paper, we review 5 recent examples where RWE was submitted in support of the FDA approvals of original or supplementary indications for oncology drugs. Methods To identify cases where RWE was used, we reviewed drug approval packages available at Drugs@FDA for oncology drugs approved between 2017 and 2019. Five cases were selected to present a broad overview of different types of RWE, different circumstances under which RWE has been used for regulatory approvals, and how FDA evaluated the data in each case. The type of RWE submitted, the indication, limitations identified by FDA reviewers, and the outcome of the submission are discussed. Results RWE, particularly historical controls for rare or orphan indications, has been used to support both original and supplementary oncology drug approvals. Types of RWE included data from electronic health records, claims, post-marketing safety reports, retrospective medical record reviews, and expanded access studies. Small sample sizes, data quality, and methodological issues were among concerns cited by FDA reviewers. Conclusion By bridging the gap between the constraints of the trial setting and the realities of clinical practice, RWE can add value to a regulatory submission. These early examples provide insight into how regulators evaluated RWE submitted as evidence of efficacy for oncology drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect